Novartis to build new radioligand therapy site in Denton, Texas, delivering more next?generation treatments to patients
MWN-AI** Summary
Novartis, a global leader in innovative medicine, recently announced plans to build a new radioligand therapy (RLT) manufacturing facility in Denton, Texas. This site, spanning 46,000 square feet, will mark Novartis' first manufacturing operation in Texas and its fifth RLT site in the United States. The project is part of the company’s larger commitment to invest $23 billion in U.S. operations, aimed at enhancing the availability of next-generation cancer therapies.
Groundbreaking for the Denton facility is set for this year, with operations anticipated to commence in 2028. This new site is expected to generate jobs in bioengineering, advanced manufacturing, and quality operations, contributing significantly to economic growth in Denton and neighboring areas. Novartis CEO Vas Narasimhan highlighted the transformative potential of RLT for cancer treatment, emphasizing the need to expand manufacturing capabilities to meet increasing patient demand for these precision therapies.
The Texas facility will join Novartis’ expansive RLT manufacturing network, which includes existing sites in New Jersey, Indiana, and California, alongside a newly announced site in Florida. This network is crucial for ensuring timely delivery of custom-made doses to patients, as RLT treatments require proximity to treatment centers due to their time-sensitive nature. Novartis' advanced pipeline includes ongoing research into RLT applications across multiple cancer types, including prostate, breast, and lung cancers.
Texas Governor Greg Abbott underscored the significance of this investment, noting its potential to bolster supply chains and expedite access to innovative cancer treatments for patients in Texas and beyond. With this development, Novartis reinforces its commitment to transforming cancer care and enhancing patient outcomes through cutting-edge therapies.
MWN-AI** Analysis
Novartis' announcement of a new radioligand therapy (RLT) manufacturing facility in Denton, Texas, is a strategic move that has significant implications for the company and investors alike. This facility is poised to bolster Novartis' RLT manufacturing network, expanding its capacity to deliver advanced cancer treatments precisely when and where they are needed.
With the facility expected to become operational by 2028, it underscores Novartis' commitment to meeting the rising demand for targeted cancer therapies amid a growing pipeline that includes various tumor types. The expansion aligns with broader trends in oncology towards personalized medicine, positioning Novartis favorably in a competitive market landscape.
Investors should view this move as a long-term investment in growth and innovation. Texas is emerging as a vital hub for biotechnology, which not only supports Novartis' operational footprint but also enhances job creation in the region, leading to local economic benefits. The establishment of this manufacturing site will likely improve logistical efficiencies by reducing the distance RLT products must travel, a critical factor given the custom and time-sensitive nature of these therapies.
Furthermore, Novartis' proactive approach—having recently broken ground on multiple facilities and expansions—signals robust strategic planning and an aggressive pursuit of market leadership in the oncology space. This investment is part of a significant $23 billion initiative aimed at bolstering the company's U.S. operations, underscoring confidence in the future of RLT as a therapy class.
In conclusion, as Novartis expands its RLT capabilities, investors should consider potential growth trajectories not only in terms of revenue from RLT but also the larger implications this facility may have on Novartis’ stock performance amid broader industry confidence in next-generation cancer treatments. It represents a timely investment in a promising sector, positioning Novartis as a leader in innovation in cancer care.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US
- Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor types
- Company broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations
East Hanover, February 25, 2026 – Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. This purpose-built RLT site will be the company’s fifth in the US and first manufacturing facility in Texas, and marks further progress in the company’s $23 billion US investment.
The Denton site is expected to create new Novartis jobs in bioengineering, advanced manufacturing, quality and operations, supporting economic growth in Denton and surrounding communities. Construction is scheduled to begin this year, with the site expected to become fully operational in 2028.
“RLT has the potential to revolutionize cancer care,” said Vas Narasimhan, CEO of Novartis. “The addition of our fifth RLT manufacturing site in the US strengthens our ability to meet growing demand, building the capabilities needed to deliver these next-generation treatments with the speed and precision they require.”
“Texas is a leading biotech hub and home to groundbreaking advancements in medicine,” said Governor Greg Abbott. “This significant investment by Novartis in Denton will establish their first manufacturing facility in Texas for cancer therapies and create good-paying jobs in bioengineering, advanced manufacturing, and more. Working together with innovative global leaders, we will continue to strengthen critical supply chains to help speed next-generation treatments to patients across Texas and the US.”
The Texas site will join a comprehensive Novartis RLT manufacturing network, with existing US sites in New Jersey, Indiana and California and a recently announced site to be constructed in Florida — providing unmatched RLT capacity from coast to coast. The manufacturing network has a longstanding record of enabling >99% of doses to be administered on the planned day. Each dose of RLT is custom-made and time-sensitive, making proximity to patients and treatment centers critical.
Novartis and radioligand therapy (RLT)
Novartis is reimagining cancer care with RLT for patients with advanced cancers. By harnessing the power of targeted radiation and applying it to advanced cancers, RLT is designed to deliver treatment directly to target cells anywhere in the body.
Novartis is actively investigating the application of RLTs across cancer types and settings, with one of the deepest and most advanced pipelines in the industry, with trials in prostate cancer, breast, colon, lung, brain, pancreatic and other cancers. Novartis has established global expertise, with specialized supply chain and manufacturing capabilities across its network of RLT production sites around the world.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release; or regarding potential future revenues from such products; or regarding discussions of strategy, plans, expectations or intentions, including discussions regarding our continued investment into new US R&D or manufacturing capabilities.. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. Neither can there be any guarantee that the expected benefits from the plans and investments described in this press release will be achieved in the expected timeframe, or at all. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.us and connect with us on LinkedIn US, X/Twitter US and Instagram US.
| Novartis Media Relations |
| E-mail: media.relations@novartis.com |
| Novartis Investor Relations |
| Central investor relations line: +41 61 324 7944 |
| E-mail: investor.relations@novartis.com |
FAQ**
How will the establishment of the new Denton facility contribute to Novartis Ag Basel Akt NVSEF’s overall RLT manufacturing capacity in the US and its capability to meet rising patient demand across different tumor types by 2028?
What are the projected economic impacts of Novartis Ag Basel Akt NVSEF's new facility in Denton on local job creation and the surrounding community by 2028, particularly in bioengineering and advanced manufacturing?
With the rapid expansion of the RLT network, how does Novartis Ag Basel Akt NVSEF plan to manage supply chain logistics to ensure timely delivery of customized RLT doses to treatment centers by 2028?
Can you provide insights into Novartis Ag Basel Akt NVSEF’s clinical trial pipeline for RLT therapies in various cancer types and how the Denton facility will support these initiatives as it becomes operational in 2028?
**MWN-AI FAQ is based on asking OpenAI questions about Novartis Ag Basel Akt (OTC: NVSEF).
NASDAQ: NVSEF
NVSEF Trading
-6.09% G/L:
$158 Last:
268 Volume:
$158 Open:
